AbbVie press release (ABBV): Q3 Non-GAAP EPS of $1.86 beats by $0.08.
Revenue of $15.78B (+9.1% Y/Y) beats by $200M.
Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million
Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 – $10.58 to $10.61 – $10.65 vs. $10.86 consensus, which Includes an Unfavorable Impact of $2.05 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025
Announces 2026 Dividend Increase of 5.5 Percent, Beginning with Dividend Payable in February 2026
